drugset / Trial / NCT00563849

Leflunomide + Methotrexate in Rheumatoid Arthritis

NCT00563849

Phase 4 Completed 74 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

To determine the efficacy and safety of the combination of leflunomide and methotrexate for treating active rheumatoid arthritis (RA) in an open noncomparative multicenter trial.

Timeline

Start
2003-05
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule 10 mg
Subject Methotrexate Small molecule 15 mg

Indications